Table 1.
Preclinical targets of therapeutic saRNAs in human cancers and renal disease.
| Gene Symbol | Full Name | Cancer | References |
|---|---|---|---|
| CDH1 | E-cadherin | Cervical cancer | [1] |
| CDKN1A (p21) | Cyclin-dependent kinase inhibitor 1A | Prostate cancer, Breast cancer, Cervical cancer, Bladder cancer Pancreatic cancer Non-small-cell lung carcinoma Liver cancer |
[1] [41] [42] [43] |
| VEGF | Vascular endothelial growth factor | Cervical cancer | [1] |
| PGR (PR) | Progesterone receptor | Breast cancer | [44] |
| MVP | Major vault protein | Breast cancer | [44] |
| KLF4 | Kruppel-like factor 4 | Prostate cancer Colorectal cancer |
[45] [46] |
| C/EBPα | CCAAT/enhancer-binding protein a | Liver cancer Pancreatic cancer |
[18, 47] [34] |
| PAWR | PRKC apoptosis WT1 regulator | Bladder cancer, prostate cancer | [48] |
| NKX3-1 | NK3 homeobox 1 | Prostate cancer | [49] |
| HIC-1 | HIC ZBTB transcriptional repressor | Breast cancer | [50] |
| NIS | Sodium/iodine symporter | Hepatocellular carcinoma | [51] |
| TP53 | Wild type p53 | Malignant pheochromocytoma | [52] |
| VHL | Von Hippel-Lindau | Renal cell carcinoma | [53] |
| TRPV5 | Transient receptor potential cation channel subfamily V member 5 | Nephrolithiasis | [39] |